| Oncorus–Cowen: investment, 201908 financing round Series B totalling $79.5m incl co-lead investor Cowen Healthcare Investments |
2019-08-21 |
| Oncorus–Perceptive Advisors: investment, 201908 financing round Series B totalling $79.5m incl co-lead investor Perceptive Advisors |
2019-08-21 |
| Oncorus–SEVERAL: investment, 201908 financing round Series B $79.5m co-led by Cowen Healthcare Investments + Perceptive Advisors |
2019-08-21 |
| Bayer–Elanco: investment, 201908– acquisition of Bayer Animal Health business for $5.3b in cash + $2.3b in shares |
2019-08-20 |
| Juvenescence–SEVERAL: investment, 201908 financing round Series B $100m incl founders + private investment companies |
2019-08-19 |
| Synpromics–AskBio: investment, 201908 acquisition of Synpromics Ltd by Asklepios Biopharmaceutical Inc |
2019-08-13 |
| Boehringer–Univ Texas: cancer drugs, 201908– collab new virtual r+d center to advance new cancer therapies incl KRAS inhibitors + TRAILR2 agonists |
2019-08-12 |
| Cavion–Jazz Pharmaceuticals: investment, 201908 acquisition $52.5m upfront + $260m milestones of Cavion Inc by Jazz |
2019-08-12 |
| Curetis–HC Wainwright: investment banking, 201908– supply service Curetis retains HC Wainwright to evaluate all strategic options |
2019-08-12 |
| BlueRock Therapeutics–Bayer: investment, 201808– acquisition 100% by acquiring remaining 59.2% for $240m upfront + $360m milestones |
2019-08-08 |
| MeiraGTx–SEVERAL: investment, 201908 public offering $75.2m+$11.28m with 3.2m+480k ordinary shares at $23.5/share |
2019-08-07 |
| Stemline Therapeutics–SEVERAL: investment, 201908 public offering $76.25m+$11.44m with 5m+575k shares common stock at $15.25/share |
2019-08-07 |
| Blue Heron–Eurofins: investment, 201908 acquisition of Blue Heron Biotech by Eurofins Genomics LLC |
2019-08-06 |
| GNA Biosolutions–GreyBird Ventures: investment, 201908 financing round Series C totalling $13.5m incl new investor GreyBird Ventures |
2019-08-05 |
| GNA Biosolutions–SEVERAL: investment, 201908 financing round Series C $13.5m from new + existing EU + US investors |
2019-08-05 |
| Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP |
2019-07-31 |
| Atlantic Healthcare–Lazar Partners: public relations, 201907 service existent US IR + media relations by Lazar Partners |
2019-07-31 |
| Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB |
2019-07-31 |
| Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company |
2019-07-31 |
| Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO |
2019-07-31 |
| Genomic Health–Exact Sciences: investment, 201907– merger acquisition $2.8b at $72/share with $1.07b in cash + $1.73b in shares ANNOUNCED |
2019-07-29 |
| 908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al |
2019-07-25 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Castle Biosciences–SEVERAL: investment, 201907 IPO $64m priced at $16/share |
2019-07-25 |
| Merck (DE)–908 Devices: biopharma production technology, 201907– collab 908 + MilliporeSigma + Univ North Carolina on bioreactor process analytics |
2019-07-25 |
| Twist Bioscience–Imagene: nucleic acid storage technology, 201907– supply service DNA encapsulation using DNAshell technology |
2019-07-25 |
| Freenome–Polaris Partners: investment, 201907 financing round Series B totalling $160m incl new + co-lead investor Polaris Partners |
2019-07-24 |
| Freenome–RA Capital Management: investment, 201907 financing round Series B totalling $160m incl new + co-lead investor RA Capital Management |
2019-07-24 |
| Freenome–Roche: investment, 201907 financing round Series B totalling $160m incl new + co-investor Roche Venture Fund |
2019-07-24 |
| Freenome–SEVERAL: investment, 201907 financing round Series B $160m co-led by RA Capital Management + Polaris Partners + incl Roche Venture Fund |
2019-07-24 |
| Freenome–W2O Group: public relations, 201907 service existent by Pure Communications |
2019-07-24 |
| Genmab–SEVERAL: investment, 201907 US IPO $581.6m with 28.5m+4.275m ADSs at $17.75/ADS with 10 ADSs/share at Nasdaq Global Select Market |
2019-07-22 |
| AvroBio–SEVERAL: investment, 201907 underwritten public offering $138.3m with 6.5m+975k shares common stock |
2019-07-19 |
| Gilead–Novartis: virostatic agents, 201907– license excl ww for three preclinical antivirals incl upfront payment plus $291m milestones + royalties |
2019-07-19 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Boehringer–Bridge Biotherapeutics: autotaxin inhibitor, 201907– collab + ww license BBT-877 up to €45m upfront/near-term + up to €1.1b + royalties |
2019-07-18 |
| Fulcrum Therapeutics–SEVERAL: investment, 201907 IPO $72m priced at $16/share |
2019-07-18 |
| Mallinckrodt–Silence Therapeutics: RNAi drugs, 201907– collab developm + commercialisation $20m upfront + milestones + royalties plus $5m investment |
2019-07-18 |
| Mirum Pharmaceuticals–SEVERAL: investment, 201907 IPO $75m priced at $15/share |
2019-07-18 |
| MIT–Merck (DE): CRISPR technology, 201907– collab pooling of IP from Merck + Broad Institute for licensing CRISPR for r+d by Broad |
2019-07-18 |
| Silence Therapeutics–Mallinckrodt: investment, 201907 investment £4m with 5m new ordinary shares at 79p/share as part of collab = 6.5% share |
2019-07-18 |
| Pyxis Oncology–Agent Capital: investment, 201907 financing round Series A totalling $22m incl co-investor Agent Capital |
2019-07-17 |
| Pyxis Oncology–Bayer: investment, 201907 financing round Series A totalling $22m incl lead investor Leaps by Bayer |
2019-07-17 |
| Pyxis Oncology–Ipsen: investment, 201907 financing round Series A totalling $22m incl co-investor Ipsen |
2019-07-17 |
| Pyxis Oncology–Longwood Fund: investment, 201907 financing round Series A totalling $22m incl co-investor Longwood Fund |
2019-07-17 |
| Pyxis Oncology–SEVERAL: investment, 201907 financing round Series A $22m led by Leaps by Bayer |
2019-07-17 |
| Bayer–Evogene: plant genomics, 201907 collaboration amendment to refocus on genome editing target discovery for corn diseases |
2019-07-16 |
| Roche–Sosei: GPCR-targeting drugs, 201907– collab multi-target research + licensing up to >$1b Genentech + Sosei Heptares |
2019-07-16 |
| Recursion Pharmaceuticals–SEVERAL: investment, 201907 financing round Series C $121m led by Baillie Gifford |
2019-07-15 |
| Galapagos–Gilead: investment, 201907 equity investment $1.1b at €140.59/share raising share from 12.3% to 22% as part of collab |
2019-07-14 |
| Gilead–Galapagos: drug research + development, 201907–202906 strategic 10y collab $3.9b upfront + $1.1b equity investment + milestones |
2019-07-14 |
| BioTek Instruments–Agilent: investment, 201907– acquisition $1.165b incl anticipated tax benefits net $1.05b |
2019-07-11 |
| BioNTech–BVCF Management: investment, 201907 financing round Series B totalling $325m incl co-investor BVCF Management |
2019-07-09 |
| BioNTech–Fidelity: investment, 201907 financing round Series B totalling $325m incl existing + lead investor Fidelity Management and Research |
2019-07-09 |
| BioNTech–Invus Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Invus |
2019-07-09 |
| BioNTech–Jebsen Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Jebsen Capital |
2019-07-09 |
| BioNTech–Mirae Asset: investment, 201907 financing round Series B totalling $325m incl co-investor Mirae Asset Financial Group |
2019-07-09 |
| BioNTech–Platinum Asset Management: investment, 201907 financing round Series B totalling $325m incl co-investor Platinum Asset Management |
2019-07-09 |
| BioNTech–Redmile Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investor Redmile Group |
2019-07-09 |
| BioNTech–SEVERAL: investment, 201907 financing round Series B $325m led by existing investor Fidelity Management and Research |
2019-07-09 |
| BioNTech–Steam Athena Capital: investment, 201907 financing round Series B totalling $325m incl co-investor Steam Athena Capital |
2019-07-09 |
| BioNTech–Strüngmann Group: investment, 201907 financing round Series B totalling $325m incl existing + co-investorStrüngmann Family Office |
2019-07-09 |
| JnJ–Celsius Therapeutics: biomarker discovery, 201907– collab to identify biomarkers for ulcerative colitis with Janssen Biotech Inc |
2019-07-09 |
| Revolution Medicines–BVF Partners: investment, 201907 financing round Series C totalling $100m incl co-investor Biotechnology Value Fund |
2019-07-09 |
| Revolution Medicines–Casdin Capital: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Casdin Capital |
2019-07-09 |
| Revolution Medicines–Column Group: investment, 201907 financing round Series C totalling $100m incl existing + co-investor The Column Group |
2019-07-09 |
| Revolution Medicines–Cormorant Asset Management: investment, 201907 financing round Series C totalling $100m incl co-investor Cormorant Capital |
2019-07-09 |
| Revolution Medicines–Deerfield Management: investment, 201907 financing round Series C totalling $100m incl co-investor Deerfield Management |
2019-07-09 |
| Revolution Medicines–Fidelity: investment, 201907 financing round Series C totalling $100m incl co-investor Fidelity Management and Research Company |
2019-07-09 |
| Revolution Medicines–Guggenheim: financial services, 201907 supply service strategic advice for $100m Series C round by Guggenheim Securities |
2019-07-09 |
| Revolution Medicines–Latham & Watkins: legal services, 201907 supply service legal counsel with regard to $100m Series C financing round |
2019-07-09 |
| Revolution Medicines–Nextech Invest: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Nextech Invest |
2019-07-09 |
| Revolution Medicines–Schroders: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Schroder Adveq |
2019-07-09 |
| Revolution Medicines–SEVERAL: investment, 201907 financing round Series C $100m led by Boxer Capital |
2019-07-09 |
| Revolution Medicines–Tavistock: investment, 201907 financing round Series C totalling $100m incl lead investor Boxer Capital |
2019-07-09 |
| Revolution Medicines–Third Rock Ventures: investment, 201907 financing round Series C totalling $100m incl existing + co-investor Third Rock Ventures |
2019-07-09 |
| Revolution Medicines–Vida Strategic Partners: public relations, 201907 service PR + IR existent by Vida Strategic Partners |
2019-07-09 |
| Revolution Medicines–Vivo Capital: investment, 201907 financing round Series C totalling $100m incl co-investor Vivo Capital |
2019-07-09 |
| IGM Biosciences–Argot Partners: public relations, 201907 service existent by Argot Partners |
2019-07-08 |
| IGM Biosciences–Haldor Topsøe: investment, 201907 financing round Series C totalling $102m incl existing + founding investor Haldor Topsøe Holding A/S |
2019-07-08 |
| IGM Biosciences–Janus Henderson: investment, 201907 financing round Series C totalling $102m incl new investor Janus Henderson Investors |
2019-07-08 |
| IGM Biosciences–Redmile Group: investment, 201907 financing round Series C totalling $102m incl new investor Redmile Group |
2019-07-08 |
| IGM Biosciences–SEVERAL: investment, 201907 financing round Series C $102m incl Redmile Group + Janus Henderson + Vivo Capital et al |
2019-07-08 |
| IGM Biosciences–Vivo Capital: investment, 201907 financing round Series C totalling $102m incl new investor Vivo Capital |
2019-07-08 |
| PMOD Technologies–Bruker Corp: investment, 201907 acquisition €na of PMOD Technologies LLC by Bruker |
2019-07-08 |
| Danaher–Cobo Technologies: protein expression analysis, 201907– collab co-marketing PIPPR platform with SWATH Acquisition + Sciex TripleTOF 6600 |
2019-07-05 |
| Oncovita–Institut Pasteur: cancer immunotherapy, 201907– license excl ww €na for use of oncolytic measles virus platform for product developm + sale |
2019-07-02 |
| Antimicrobials Working Group–Amplyx Pharmaceuticals: antibiotics, 201907– collab existent Amplyx is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–Aridis Pharmaceuticals: antibiotics, 201907– collab existent Aridis is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–Cidara Therapeutics: antibiotics, 201907– collab existent Cidara is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–ContraFect: antibiotics, 201907– collab existent ContraFect Corp is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–Entasis Therapeutics: antibiotics, 201907– collab existent Entasis is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–Iterum Therapeutics: antibiotics, 201907– collab existent Iterum is member of AWG |
2019-07-01 |
| Antimicrobials Working Group–X-Biotix Therapeutics: antibiotics, 201907– collab X-Biotix becomes member of AWG |
2019-07-01 |
| Century Therapeutics–Bayer: investment, 201907 financing round totalling $250m commitments incl $215m from Leaps by Bayer |
2019-07-01 |
| Century Therapeutics–Fujifilm: investment, 201907 financing round totalling $250m commitments incl co-investor Fujifilm Cellular Dynamics Inc |
2019-07-01 |
| Century Therapeutics–SEVERAL: investment, 201907 financing round $250m commitments from Leaps by Bayer + Versant Ventures + Fujifilm CDI |
2019-07-01 |
| Century Therapeutics–Versant Ventures: investment, 201907 financing round totalling $250m commitments incl existing + co-investor Versant Ventures |
2019-07-01 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo-2019.png){kind=logo}
Date![Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px](/banner/iito-20190704-650-099-life-sciences-uk-telegram.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lse-life-sciences-europe-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
